The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,288
Sort by:
Kanuma- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kanuma ...
January 2019
35 pages
Kengreal- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kengreal ...
January 2019
35 pages
Kevzara- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kevzara ...
January 2019
35 pages
Keytruda- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Keytruda ...
January 2019
35 pages
Kisqali- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kisqali ...
January 2019
35 pages
Kybella- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kybella ...
January 2019
35 pages
Kynamro- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kynamro ...
January 2019
35 pages
Lartruvo- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lartruvo ...
January 2019
35 pages
Lenvima- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lenvima ...
January 2019
35 pages
Lonsurf- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lonsurf ...
January 2019
35 pages
Lovenox- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lovenox ...
January 2019
35 pages
Luzu- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Luzu ...
January 2019
35 pages
Lynparza- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lynparza ...
January 2019
35 pages
Mekinist- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mekinist ...
January 2019
35 pages
Movantik- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Movantik ...
January 2019
35 pages
Myalept- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Myalept ...
January 2019
35 pages
Natpara- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Natpara ...
January 2019
35 pages
Ninlaro- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ninlaro ...
January 2019
35 pages
Northera- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Northera ...
January 2019
35 pages
Nucala- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nucala ...
January 2019
35 pages
Nuplazid- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nuplazid ...
January 2019
35 pages
Ocaliva- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ocaliva ...
January 2019
35 pages
Ofev- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ofev ...
January 2019
35 pages
Olysio- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Olysio ...
January 2019
35 pages
Opdivo- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Opdivo ...
January 2019
35 pages
Opsumit- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Opsumit ...
January 2019
35 pages
Orbactiv- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Orbactiv ...
January 2019
35 pages
Orkambi- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Orkambi ...
January 2019
35 pages
Osphena- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Osphena ...
January 2019
35 pages
Otezla- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Otezla ...
January 2019
35 pages
Pomalyst- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Pomalyst ...
January 2019
35 pages
Portrazza- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Portrazza ...
January 2019
35 pages
Praluent- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Praluent ...
January 2019
35 pages
Premarin- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Premarin ...
January 2019
35 pages
Protopic- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Protopic ...
January 2019
35 pages
Rapivab- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Rapivab ...
January 2019
35 pages
Repatha- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Repatha ...
January 2019
35 pages
Requip- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Requip ...
January 2019
35 pages
Revatio- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Revatio ...
January 2019
35 pages
Rexulti- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Rexulti ...
January 2019
35 pages
Risperdal Consta- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Risperdal Consta ...
January 2019
35 pages
Rubraca- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Rubraca ...
January 2019
35 pages
Savaysa- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Savaysa ...
January 2019
35 pages
Siliq- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Siliq ...
January 2019
35 pages
Sivextro Oral- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Sivextro Oral ...
January 2019
35 pages
Sovaldi- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Sovaldi ...
January 2019
35 pages
Spinraza- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Spinraza ...
January 2019
35 pages
Strensiq- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Strensiq ...
January 2019
35 pages
Striverdi Respimat- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Striverdi Respimat ...
January 2019
35 pages
Tafinlar- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Tafinlar ...
January 2019
35 pages
